BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kumada T, Toyoda H, Tada T, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Niinomi T, Yasuda S, Andou Y, Yamamoto K, Tanaka J. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427-433. [PMID: 23123221 DOI: 10.1016/j.jhep.2012.10.025] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabatake S, Yama T, Tanaka J. HBcrAg predicts hepatocellular carcinoma development: An analysis using time-dependent receiver operating characteristics. Journal of Hepatology 2016;65:48-56. [DOI: 10.1016/j.jhep.2016.03.013] [Cited by in Crossref: 75] [Cited by in F6Publishing: 71] [Article Influence: 12.5] [Reference Citation Analysis]
2 Zhang M, Wang D, Liu H, Li H. Tenofovir decrease hepatocellular carcinoma recurrence in chronic hepatitis B patients after liver resection. Infect Agent Cancer 2018;13:19. [PMID: 29977330 DOI: 10.1186/s13027-018-0191-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kozuka R, Enomoto M, Sato-Matsubara M, Yoshida K, Motoyama H, Hagihara A, Fujii H, Uchida-Kobayashi S, Morikawa H, Tamori A, Kawada N, Murakami Y. Association between HLA-DQA1/DRB1 polymorphism and development of hepatocellular carcinoma during entecavir treatment. J Gastroenterol Hepatol 2019;34:937-46. [PMID: 30160782 DOI: 10.1111/jgh.14454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
4 Choi J, Lim Y. Nucleos(t)ide Therapy and Long-Term Outcomes. In: Kao J, Chen D, editors. Hepatitis B Virus and Liver Disease. Singapore: Springer; 2018. pp. 193-217. [DOI: 10.1007/978-981-10-4843-2_11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
5 Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP. The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy. Aliment Pharmacol Ther. 2014;40:1262-1269. [PMID: 25312649 DOI: 10.1111/apt.12990] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
6 Khoo T, Lam D, Olynyk JK. Impact of modern antiviral therapy of chronic hepatitis B and C on clinical outcomes of liver disease. World J Gastroenterol 2021; 27(29): 4831-4845 [PMID: 34447229 DOI: 10.3748/wjg.v27.i29.4831] [Reference Citation Analysis]
7 Papatheodoridis GV, Dalekos GN, Yurdaydin C, Buti M, Goulis J, Arends P, Sypsa V, Manolakopoulos S, Mangia G, Gatselis N, Keskın O, Savvidou S, Hansen BE, Papaioannou C, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. Journal of Hepatology 2015;62:363-70. [DOI: 10.1016/j.jhep.2014.08.045] [Cited by in Crossref: 107] [Cited by in F6Publishing: 106] [Article Influence: 15.3] [Reference Citation Analysis]
8 Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423-431. [PMID: 28081591 DOI: 10.3350/cmh.2016.0069] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
9 Inoue T, Kusumoto S, Iio E, Ogawa S, Suzuki T, Yagi S, Kaneko A, Matsuura K, Aoyagi K, Tanaka Y. Clinical efficacy of a novel, high-sensitivity HBcrAg assay in the management of chronic hepatitis B and HBV reactivation. J Hepatol 2021;75:302-10. [PMID: 33762167 DOI: 10.1016/j.jhep.2021.02.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
10 Janssen HL, Arif A. Averting hepatocellular carcinoma in chronic hepatitis B with antiviral therapy: tipping the balance or not yet? Gastroenterology 2014;147:24-6. [PMID: 24877866 DOI: 10.1053/j.gastro.2014.05.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Kotha S, Neong S, Patel K. Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma. Expert Rev Mol Diagn 2018;18:713-22. [PMID: 30019978 DOI: 10.1080/14737159.2018.1496020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
12 Chien RN, Kao JH, Peng CY, Chen CH, Liu CJ, Huang YH, Hu TH, Yang HI, Lu SN, Ni YH, Chuang WL, Lee CM, Wu JC, Chen PJ, Liaw YF. Taiwan consensus statement on the management of chronic hepatitis B. J Formos Med Assoc. 2019;118:7-38. [PMID: 30527436 DOI: 10.1016/j.jfma.2018.11.008] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
13 Rui S, Yan J, Zhang H, Wang Z, Zhou W. Intermediate-stage hepatocellular carcinoma patients with a high HBV-DNA load may benefit from postoperative anti-hepatitis B virus therapy. Medicine (Baltimore) 2017;96:e7608. [PMID: 28746212 DOI: 10.1097/MD.0000000000007608] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
14 Yim HJ, Kim JH, Park JY, Yoon EL, Park H, Kwon JH, Sinn DH, Lee SH, Lee JH, Lee HW. Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop. Clin Mol Hepatol. 2020;26:411-429. [PMID: 32854458 DOI: 10.3350/cmh.2020.0049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
15 Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1076] [Cited by in F6Publishing: 1014] [Article Influence: 153.7] [Reference Citation Analysis]
16 Mak LY, Wong DK, Cheung KS, Seto WK, Lai CL, Yuen MF. Review article: hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43-54. [PMID: 29035003 DOI: 10.1111/apt.14376] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 16.0] [Reference Citation Analysis]
17 Kim MN, Hwang SG, Kim BK, Park JY, Kim DY, Han KH, Kim SU, Ahn SH. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Gut Liver 2019;13:197-205. [PMID: 30602075 DOI: 10.5009/gnl18204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
18 Papatheodoridis GV, Idilman R, Dalekos GN, Buti M, Chi H, van Boemmel F, Calleja JL, Sypsa V, Goulis J, Manolakopoulos S. The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. Hepatology. 2017;66:1444-1453. [PMID: 28622419 DOI: 10.1002/hep.29320] [Cited by in Crossref: 151] [Cited by in F6Publishing: 146] [Article Influence: 30.2] [Reference Citation Analysis]
19 Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014;60:87-97. [PMID: 24585488 DOI: 10.1002/hep.27102] [Cited by in Crossref: 149] [Cited by in F6Publishing: 119] [Article Influence: 18.6] [Reference Citation Analysis]
20 Seto WK, Wong DK, Fung J, Huang FY, Liu KS, Lai CL, Yuen MF. Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect. 2014;20:1173-1180. [PMID: 24975365 DOI: 10.1111/1469-0691.12739] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 8.3] [Reference Citation Analysis]
21 Watanabe T, Inoue T, Tanaka Y. Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B. Microorganisms 2021;9:2083. [PMID: 34683404 DOI: 10.3390/microorganisms9102083] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
22 Tada T, Kumada T, Toyoda H, Kobayashi N, Akita T, Tanaka J. Hepatitis B virus core-related antigen levels predict progression to liver cirrhosis in hepatitis B carriers. J Gastroenterol Hepatol. 2018;33:918-925. [PMID: 28914957 DOI: 10.1111/jgh.13989] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
23 Matsuda S, Maekawa S, Komiyama Y, Nakakuki N, Muraoka M, Suzuki Y, Sato M, Tatsumi A, Miura M, Amemiya F, Shindo H, Takano S, Fukasawa M, Yamaguchi T, Nakayama Y, Inoue T, Sato T, Yamashita A, Moriishi K, Enomoto N. Deep sequencing analysis of serum hepatitis B virus-RNA during nucleot(s)ide analogue therapy. Hepatol Res 2021;51:39-50. [PMID: 32961003 DOI: 10.1111/hepr.13574] [Reference Citation Analysis]
24 Aoki T, Iijima H, Tada T, Kumada T, Nishimura T, Nakano C, Kishino K, Shimono Y, Yoh K, Takata R, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Hirota S, Fujimoto J, Nishiguchi S. Prediction of development of hepatocellular carcinoma using a new scoring system involving virtual touch quantification in patients with chronic liver diseases. J Gastroenterol 2017;52:104-12. [DOI: 10.1007/s00535-016-1228-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
25 Varbobitis I, Papatheodoridis GV. The assessment of hepatocellular carcinoma risk in patients with chronic hepatitis B under antiviral therapy. Clin Mol Hepatol. 2016;22:319-326. [PMID: 27729632 DOI: 10.3350/cmh.2016.0045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
26 Kumada T, Toyoda H, Tada T, Yasuda S, Tanaka J. Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade. Liver Cancer 2020;9:518-28. [PMID: 33083278 DOI: 10.1159/000507933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
27 Kaneko S, Kurosaki M, Joko K, Marusawa H, Kondo M, Kojima Y, Uchida Y, Kimura H, Tsuji K, Yagisawa H, Kusakabe A, Kobashi H, Akahane T, Tamaki N, Kirino S, Abe T, Yoshida H, Matsushita T, Hasebe C, Izumi N. Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. Sci Rep. 2020;10:13021. [PMID: 32747646 DOI: 10.1038/s41598-020-69522-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Hiramatsu N, Yamada R, Takehara T. The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients. J Gastroenterol Hepatol. 2016;31:546-552. [PMID: 26574149 DOI: 10.1111/jgh.13229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
29 Block TM, Locarnini S, McMahon BJ, Rehermann B, Peters MG. Use of Current and New Endpoints in the Evaluation of Experimental Hepatitis B Therapeutics. Clin Infect Dis 2017;64:1283-8. [PMID: 28200098 DOI: 10.1093/cid/cix129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
30 Vachon A, Osiowy C. Novel Biomarkers of Hepatitis B Virus and Their Use in Chronic Hepatitis B Patient Management. Viruses 2021;13:951. [PMID: 34064049 DOI: 10.3390/v13060951] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
31 Bowden S, Locarnini S, Chang TT, Chao YC, Han KH, Gish RG, de Man RA, Yu M, Llamoso C, Tang H. Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World J Gastroenterol 2015; 21(15): 4644-4651 [PMID: 25914474 DOI: 10.3748/wjg.v21.i15.4644] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
32 Jian ZW, Wu XW, Chen ZX, Wang JC, Peng JY, Lao XM. Effect of Nucleos(t)ide Analogs on Patients with Intermediate and Advanced Hepatitis B Virus-Related Hepatocellular Carcinoma. Dig Dis Sci 2019;64:2187-98. [PMID: 30815819 DOI: 10.1007/s10620-019-05543-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
33 Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clin Microbiol Rev. 2020;33. [PMID: 32102898 DOI: 10.1128/cmr.00046-19] [Cited by in Crossref: 37] [Cited by in F6Publishing: 20] [Article Influence: 18.5] [Reference Citation Analysis]
34 Akuta N, Suzuki F, Kobayashi M, Hara T, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Saitoh S, Ikeda K. Correlation between hepatitis B virus surface antigen level and alpha-fetoprotein in patients free of hepatocellular carcinoma or severe hepatitis. J Med Virol. 2014;86:131-138. [PMID: 24123090 DOI: 10.1002/jmv.23790] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
35 Wong GL, Tse YK, Yip TC, Chan HL, Tsoi KK, Wong VW. Long-term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk - a cohort study of 44 494 subjects. Aliment Pharmacol Ther 2017;45:1213-24. [PMID: 28239880 DOI: 10.1111/apt.14015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
36 Hayashi S, Nagaoka K, Tanaka Y. Blood-Based Biomarkers in Hepatitis B Virus-Related Hepatocellular Carcinoma, Including the Viral Genome and Glycosylated Proteins. Int J Mol Sci 2021;22:11051. [PMID: 34681709 DOI: 10.3390/ijms222011051] [Reference Citation Analysis]
37 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
38 Inoue T, Tanaka Y. The Role of Hepatitis B Core-Related Antigen. Genes (Basel) 2019;10:E357. [PMID: 31075974 DOI: 10.3390/genes10050357] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
39 Gordon SC, Lamerato LE, Rupp LB, Li J, Holmberg SD, Moorman AC, Spradling PR, Teshale EH, Vijayadeva V, Boscarino JA, Henkle EM, Oja-Tebbe N, Lu M; CHeCS Investigators. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Clin Gastroenterol Hepatol 2014;12:885-93. [PMID: 24107395 DOI: 10.1016/j.cgh.2013.09.062] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
40 Fung J, Lai CL, Yuen MF. Management of chronic hepatitis B in severe liver disease. World J Gastroenterol 2014; 20(43): 16053-16061 [PMID: 25473157 DOI: 10.3748/wjg.v20.i43.16053] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
41 Tanaka E, Matsumoto A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B. Hepatol Res. 2014;44:1-8. [PMID: 23607862 DOI: 10.1111/hepr.12108] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
42 Matsumoto A, Nishiguchi S, Enomoto H, Tanaka Y, Shinkai N, Okuse C, Kang JH, Matsui T, Miyase S, Yatsuhashi H, Nagaoka S, Kanda T, Enomoto M, Yamada R, Hiramatsu N, Saito S, Takaguchi K, Ito K, Masaki T, Morihara D, Tsuge M, Chayama K, Ikeda F, Kagawa T, Kondo Y, Murata K, Tanaka E. Pilot study of tenofovir disoproxil fumarate and pegylated interferon-alpha 2a add-on therapy in Japanese patients with chronic hepatitis B. J Gastroenterol 2020;55:977-89. [PMID: 32666202 DOI: 10.1007/s00535-020-01707-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
43 Pellicelli AM, Vignally P, Messina V, Izzi A, Mazzoni E, Barlattani A, Bacca D, Romano M, Mecenate F, Stroffolini T, Furlan C, Picardi A, Gentilucci UV, Gulminetti R, Bonaventura ME, Villani R, D’ambrosio C, Paffetti A, Mastropietro C, Marignani M, Fondacaro L, Cerasari G, Andreoli A, Barbarini G. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. Annals of Hepatology 2014;13:376-85. [DOI: 10.1016/s1665-2681(19)30844-0] [Cited by in Crossref: 6] [Article Influence: 0.8] [Reference Citation Analysis]
44 Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther. 2015;42:1182-1191. [PMID: 26381928 DOI: 10.1111/apt.13409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
45 Lee HW, Ahn SH, Chan HL. Hepatitis B Core-Related Antigen: From Virology to Clinical Application. Semin Liver Dis 2021;41:182-90. [PMID: 33957693 DOI: 10.1055/s-0041-1723088] [Reference Citation Analysis]
46 Matsumoto A, Nishiguchi S, Enomoto H, Kang JH, Tanaka Y, Shinkai N, Kurosaki M, Enomoto M, Kanda T, Yokosuka O, Yatsuhashi H, Nagaoka S, Okuse C, Kagawa T, Mine T, Takaguchi K, Saito S, Hino K, Ikeda F, Sakisaka S, Morihara D, Miyase S, Tsuge M, Chayama K, Hiramatsu N, Suzuki Y, Murata K, Tanaka E. Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy. J Gastroenterol. 2018;53:247-257. [PMID: 28634723 DOI: 10.1007/s00535-017-1360-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
47 Wallace MC, Preen D, Jeffrey GP, Adams LA. The evolving epidemiology of hepatocellular carcinoma: a global perspective. Expert Rev Gastroenterol Hepatol. 2015;9:765-779. [PMID: 25827821 DOI: 10.1586/17474124.2015.1028363] [Cited by in Crossref: 181] [Cited by in F6Publishing: 179] [Article Influence: 25.9] [Reference Citation Analysis]
48 Kirino S, Tamaki N, Kurosaki M, Inada K, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Izumi N. Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. J Viral Hepat 2021;28:787-94. [PMID: 33484033 DOI: 10.1111/jvh.13473] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
49 Kumada T, Toyoda H, Yasuda S, Ito T, Tanaka J. Mortality of inactive hepatitis B virus carriers in Japan is similar to that of the general population. Hepatol Res 2022;52:81-92. [PMID: 34665918 DOI: 10.1111/hepr.13723] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
50 Kumada T, Toyoda H, Yasuda S, Miyake N, Ito T, Tanaka J. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis. J Viral Hepat 2021;28:508-16. [PMID: 33306854 DOI: 10.1111/jvh.13457] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Kumada T, Toyoda H, Tada T, Yasuda S, Miyake N, Tanaka J. Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels. Eur J Gastroenterol Hepatol 2021;32:255-60. [PMID: 32282538 DOI: 10.1097/MEG.0000000000001733] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Tamaki N, Kurosaki M, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Itakura J, Takahashi Y, Enomoto N, Izumi N. Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. JGH Open 2020;4:429-32. [PMID: 32514449 DOI: 10.1002/jgh3.12273] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
53 Baran B. Nucleos(t)ide analogs in the prevention of hepatitis B virus related hepatocellular carcinoma. World J Hepatol 2015; 7(13): 1742-1754 [PMID: 26167247 DOI: 10.4254/wjh.v7.i13.1742] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
54 Wang Y, Xiang X, Chen L, Cao Z, Bao R, Zhou H, Tang W, Lu J, Lin L, Xie Q, Bao S, Wang H. Randomized clinical trial: Nucleos(t)ide analogues improved survival of CHB-related HCC patients via reducing severity and progression of malignancy. Oncotarget 2016;7:58553-62. [PMID: 27329718 DOI: 10.18632/oncotarget.10155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
55 Ito T, Kumada T, Toyoda H, Tada T. FIB-4 index for assessing the prognosis of hepatocellular carcinoma in patients with Child-Pugh class A liver function. J Cancer Res Clin Oncol. 2015;141:1311-1319. [PMID: 25648362 DOI: 10.1007/s00432-015-1922-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
56 Hwang S, Song GW, Jung DH, Yoon YI, Yoo HJ, Tak E. High-dose tenofovir is not effective in suppressing hepatitis B virus replication in patients with hepatocellular carcinoma progression: a preliminary result. Korean J Hepatobiliary Pancreat Surg 2016;20:8-11. [PMID: 26925144 DOI: 10.14701/kjhbps.2016.20.1.8] [Reference Citation Analysis]
57 Ren M, Li J, Xue R, Wang Z, Coll SL, Meng Q. Liver function and energy metabolism in hepatocellular carcinoma developed in patients with hepatitis B-related cirrhosis. Medicine (Baltimore) 2019;98:e15528. [PMID: 31083199 DOI: 10.1097/MD.0000000000015528] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
58 Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol. 2015;62:956-967. [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002] [Cited by in Crossref: 247] [Cited by in F6Publishing: 243] [Article Influence: 35.3] [Reference Citation Analysis]
59 Jiang XY, Huang B, Huang DP, Wei CS, Zhong WC, Peng DT, Huang FR, Tong GD. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. World J Gastroenterol 2021; 27(11): 1101-1116 [PMID: 33776376 DOI: 10.3748/wjg.v27.i11.1101] [Reference Citation Analysis]
60 Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter. Hepatol Res. 2019;49:1207-1217. [PMID: 31219667 DOI: 10.1111/hepr.13391] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
61 Inoue T, Tanaka Y. Novel biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol 2020;26:261-79. [PMID: 32536045 DOI: 10.3350/cmh.2020.0032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 7.5] [Reference Citation Analysis]
62 Weng M, Zeng WZ, Wu XL, Zhang Y, Jiang MD, Wang Z, Zhou DJ, He X. Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure. Virol J 2013;10:277. [PMID: 24010768 DOI: 10.1186/1743-422X-10-277] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
63 Li S, Li H, Xiong Y, Liu F, Peng M, Zhang D, Ren H, Hu P. Peginterferon is preferable to entecavir for prevention of unfavourable events in patients with HBeAg-positive chronic hepatitis B: A five-year observational cohort study. J Viral Hepat 2017;24:12-20. [DOI: 10.1111/jvh.12755] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
64 Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, Wang X, Shimakami T, Okada H, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma. J Infect Dis. 2016;213:1096-1106. [PMID: 26621908 DOI: 10.1093/infdis/jiv572] [Cited by in Crossref: 52] [Cited by in F6Publishing: 59] [Article Influence: 7.4] [Reference Citation Analysis]
65 Chan SL, Wong VW, Qin S, Chan HL. Infection and Cancer: The Case of Hepatitis B. J Clin Oncol. 2016;34:83-90. [PMID: 26578611 DOI: 10.1200/jco.2015.61.5724] [Cited by in Crossref: 81] [Cited by in F6Publishing: 41] [Article Influence: 11.6] [Reference Citation Analysis]
66 Lo GH. Does antiplatelet therapy really reduce the risk of hepatocellular carcinoma in hepatitis B patients with antiviral drugs? Hepatology 2018;67:1642-3. [PMID: 29356042 DOI: 10.1002/hep.29794] [Reference Citation Analysis]
67 Ridruejo E. Does hepatitis B virus therapy reduce the risk of hepatocellular carcinoma? Expert Opin Drug Saf 2015;14:439-51. [PMID: 25547687 DOI: 10.1517/14740338.2015.998649] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
68 Okada M, Enomoto M, Kawada N, Nguyen MH. Effects of antiviral therapy in patients with chronic hepatitis B and cirrhosis. Expert Rev Gastroenterol Hepatol. 2017;11:1095-1104. [PMID: 28752768 DOI: 10.1080/17474124.2017.1361822] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
69 Tsuge M. The association between hepatocarcinogenesis and intracellular alterations due to hepatitis B virus infection. Liver Int 2021. [PMID: 34559952 DOI: 10.1111/liv.15065] [Reference Citation Analysis]
70 Liu Y, Veeraraghavan V, Pinkerton M, Fu J, Douglas MW, George J, Tu T. Viral Biomarkers for Hepatitis B Virus-Related Hepatocellular Carcinoma Occurrence and Recurrence. Front Microbiol 2021;12:665201. [PMID: 34194408 DOI: 10.3389/fmicb.2021.665201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Suzuki F, Hosaka T, Imaizumi M, Kobayashi M, Ohue C, Suzuki Y, Fujiyama S, Kawamura Y, Sezaki H, Akuta N, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H. Potential of ultra‐highly sensitive immunoassays for hepatitis B surface and core‐related antigens in patients with or without development of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Hepatology Research 2021;51:426-35. [DOI: 10.1111/hepr.13602] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
72 Tsai M, Chen C, Hu T, Lu S, Lee C, Wang J, Hung C. Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs. Journal of the Formosan Medical Association 2017;116:512-21. [DOI: 10.1016/j.jfma.2016.08.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
73 To WP, Mak LY, Wong DK, Fung J, Liu F, Seto WK, Lai CL, Yuen MF. Hepatitis B core-related antigen levels after HBeAg seroconversion is associated with the development of hepatocellular carcinoma. J Viral Hepat 2019;26:1473-80. [PMID: 31418973 DOI: 10.1111/jvh.13191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
74 Wen X, Yin S, Cui L, Mao L, Lin Z, Yaermaimaiti Z, Geng X, Li Y, Yang Y, Cui D, Mao Z. The Effects of the National Centralized Drug Purchasing Pilot Program on Nucleos(t)ide Analogs in Shenzhen City: An Interrupted Time Series Analysis. Front Public Health 2021;9:718013. [PMID: 34760861 DOI: 10.3389/fpubh.2021.718013] [Reference Citation Analysis]
75 Tamaki N, Kurosaki M, Nakanishi H, Itakura J, Inada K, Kirino S, Yamashita K, Osawa L, Sekiguchi S, Hayakawa Y, Wang W, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Takahashi Y, Izumi N. Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. J Med Virol 2020;92:1355-8. [PMID: 31994737 DOI: 10.1002/jmv.25692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
76 Tada T, Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Kitabtake S, Ito T. Long-term prognosis of patients with hepatitis B infection: causes of death and utility of nucleos(t)ide analogue therapy. J Gastroenterol 2015;50:795-804. [DOI: 10.1007/s00535-014-1011-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
77 Suzuki Y, Maekawa S, Komatsu N, Sato M, Tatsumi A, Miura M, Matsuda S, Muraoka M, Nakakuki N, Shindo H, Amemiya F, Takano S, Fukasawa M, Nakayama Y, Yamaguchi T, Inoue T, Sato T, Sakamoto M, Yamashita A, Moriishi K, Enomoto N. Hepatitis B virus (HBV)-infected patients with low hepatitis B surface antigen and high hepatitis B core-related antigen titers have a high risk of HBV-related hepatocellular carcinoma. Hepatol Res 2019;49:51-63. [PMID: 30350374 DOI: 10.1111/hepr.13277] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
78 Shinkai N, Nojima M, Iio E, Matsunami K, Toyoda H, Murakami S, Inoue T, Ogawa S, Kumada T, Tanaka Y. High levels of serum Mac-2-binding protein glycosylation isomer (M2BPGi) predict the development of hepatocellular carcinoma in hepatitis B patients treated with nucleot(s)ide analogues. J Gastroenterol 2018;53:883-9. [PMID: 29288305 DOI: 10.1007/s00535-017-1424-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
79 Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Tanaka J. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic: HCC development in CHB during NA therapy. Journal of Gastroenterology and Hepatology 2017;32:451-8. [DOI: 10.1111/jgh.13473] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
80 Lok AS, McMahon BJ, Brown RS Jr, Wong JB, Ahmed AT, Farah W, Almasri J, Alahdab F, Benkhadra K, Mouchli MA, Singh S, Mohamed EA, Abu Dabrh AM, Prokop LJ, Wang Z, Murad MH, Mohammed K. Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology. 2016;63:284-306. [PMID: 26566246 DOI: 10.1002/hep.28280] [Cited by in Crossref: 239] [Cited by in F6Publishing: 231] [Article Influence: 34.1] [Reference Citation Analysis]
81 Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. Int J Mol Sci. 2020;21. [PMID: 32023902 DOI: 10.3390/ijms21030949] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
82 Caviglia GP, Abate ML, Noviello D, Olivero A, Rosso C, Troshina G, Ciancio A, Rizzetto M, Saracco GM, Smedile A. Hepatitis B core-related antigen kinetics in chronic hepatitis B virus genotype D-infected patients treated with nucleos(t)ide analogues or pegylated-interferon-α: HBcrAg kinetics in CHB therapy. Hepatol Res 2017;47:747-54. [DOI: 10.1111/hepr.12811] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
83 Maasoumy B, Wiegand SB, Jaroszewicz J, Bremer B, Lehmann P, Deterding K, Taranta A, Manns MP, Wedemeyer H, Glebe D, Cornberg M. Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D. Clin Microbiol Infect 2015;21:606.e1-10. [PMID: 25700889 DOI: 10.1016/j.cmi.2015.02.010] [Cited by in Crossref: 61] [Cited by in F6Publishing: 63] [Article Influence: 8.7] [Reference Citation Analysis]
84 Trinchet JC. Hepatocellular carcinoma in 2014: current situation and future prospects. Diagn Interv Imaging. 2014;95:705-708. [PMID: 24768454 DOI: 10.1016/j.diii.2014.04.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
85 Wu C, Lin J. The changing epidemiology of Asian digestive cancers: From etiologies and incidences to preventive strategies. Best Practice & Research Clinical Gastroenterology 2015;29:843-53. [DOI: 10.1016/j.bpg.2015.09.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
86 Ando Y, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Ishikawa T, Nakano I, Hirooka Y, Goto H. Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analog treatment. Hepatol Res 2018;48:E240-51. [PMID: 28865403 DOI: 10.1111/hepr.12976] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
87 Chuaypen N, Posuwan N, Payungporn S, Tanaka Y, Shinkai N, Poovorawan Y, Tangkijvanich P. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int 2016;36:827-36. [DOI: 10.1111/liv.13046] [Cited by in Crossref: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
88 Wang JP, Kao F, Wu C, Hung Y, Chao Y, Chou Y, Li C. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population-based cohort study: NAs Reduce Risk of HCC in Chronic Hepatitis B. Cancer 2015;121:1446-55. [DOI: 10.1002/cncr.29159] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
89 Sohn W, Cho JY, Kim JH, Lee JI, Kim HJ, Woo MA, Jung SH, Paik YH. Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B. Clin Mol Hepatol 2017;23:170-8. [PMID: 28506056 DOI: 10.3350/cmh.2016.0086] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 4.8] [Reference Citation Analysis]
90 Lin D, Yang HI, Nguyen N, Hoang J, Kim Y, Vu V, Le A, Chaung K, Nguyen V, Trinh H, Li J, Zhang J, Hsing A, Chen CJ, Nguyen MH. Reduction of chronic hepatitis B-related hepatocellular carcinoma with anti-viral therapy, including low risk patients. Aliment Pharmacol Ther. 2016;44:846-855. [PMID: 27549411 DOI: 10.1111/apt.13774] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
91 Cheung KS, Seto WK, Wong DK, Lai CL, Yuen MF. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017;24:654-661. [PMID: 28185363 DOI: 10.1111/jvh.12688] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
92 Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model. Eur J Gastroenterol Hepatol 2019;31:1452-9. [PMID: 31082998 DOI: 10.1097/MEG.0000000000001434] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
93 Suzuki T, Matsuura K, Nagura Y, Iio E, Ogawa S, Fujiwara K, Nojiri S, Kataoka H, Tanaka Y. Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection. PLoS One 2021;16:e0261878. [PMID: 34962955 DOI: 10.1371/journal.pone.0261878] [Reference Citation Analysis]
94 Colombo M, Iavarone M. Role of antiviral treatment for HCC prevention. Best Pract Res Clin Gastroenterol 2014;28:771-81. [PMID: 25260307 DOI: 10.1016/j.bpg.2014.07.017] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]